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Introduction
Recurrent and chronic middle ear diseases such as 
otitis media with effusion (OME) and recurrent 
acute otitis media (RAOM) are common in otorhi-
nolaryngological and paediatric clinical practice, 
frequently associated with chronic adenoiditis.1 
Given the ineffectiveness of medical therapy and 
the low spontaneous resolution rate, persistent 
OME generally requires surgical treatment,2 which 
usually consists of tympanostomy tube placement 
with or without traditional adenoidectomy,2 
although it has recently been reported 
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hearing loss (CHL) (P value = 0.008) and those with moderate CHL (P value = 0.048) was significant in the study group, 
but not in the control group. The mean auditory threshold had also significantly improved by the end of treatment in the 
study group (P value = 0.004) but not in the control group. Our findings confirm the safety of intermittent treatment with 
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that transoral microdebrider endoscopic-assisted 
adenoidectomy may lead to better audiological 
outcomes than traditional adenoidectomy in chil-
dren with OME and mild hearing loss associated 
with chronic adenoiditis.3 Various interventions 
have been proposed to reduce the risk of new acute 
otitis media episodes in children with RAOM, but 
none is completely effective, and their benefits in 
terms of preventing RAOM have not been pre-
cisely quantified.1,4
We have recently evaluated the in vitro anti-
adhesive and anti-biofilm effects of hyaluronic 
acid (HA; an endogenous component of the extra-
cellular matrix that is involved in airway healing 
and homeostasis) on the bacterial species fre-
quently isolated from patients with upper respira-
tory tract infection.5 The results showed that HA 
interferes with bacterial adhesion (the first step in 
biofilm formation) to Hep-2 cells in a concentra-
tion-dependent manner and also moderately inhib-
its the formation of biofilm itself. However, despite 
the positive preliminary results of clinical studies 
in patients with recurrent upper airway infections 
or allergic and non-allergic rhinitis, and those 
undergoing functional endoscopic sinus surgery,6–8 
there are no published data concerning the effec-
tiveness of HA treatment in children with recurrent 
and chronic middle ear diseases.
The aim of this study was to assess the efficacy 
and safety of the topical nasal administration of an 
HA-based compound by investigating its effects 
on otoscopic and audiological findings in children 
with OME and/or a history of RAOM associated 
with chronic adenoiditis.
Materials and methods
Study design and setting
This prospective, single-blind, randomised con-
trolled study was carried out at the University of 
Milan’s Department of Clinical Sciences and 
Community Health between November 2014 and 
April 2015 and is part of a larger project aimed at 
evaluating the efficacy of the topical nasal admin-
istration of an HA-based compound in children 
with recurrent or chronic middle ear inflammation 
associated with chronic adenoiditis by assessing 
various clinical, instrumental, cytological and 
microbiological outcomes.
The protocol was approved by our local Ethics 
Committee and was conducted in accordance with 
the standards of Good Clinical Practice; written 
informed consent was obtained from the children’s 
parents or legal guardians.
Study participants
The study involved children aged 3–12 years with 
OME (defined as the presence of middle ear effu-
sion without any signs of concomitant acute mid-
dle ear inflammation for at least 3 months and 
documented by means of pneumatic otoscopy and 
tympanometry)9 and/or a history of RAOM 
(defined as three episodes in the preceding 6 
months, with the most recent episode occurring at 
least 4 weeks before study entry, and no more than 
four episodes in the preceding 12 months),10 asso-
ciated with chronic adenoiditis as previously 
defined.3 The episodes of acute otitis media were 
documented by the children’s medical records and 
had to include any combination of fever, earache, 
irritability and hyperaemia or opacity accompanied 
by bulging of the tympanic membrane or otor-
rhoea. At least two episodes had to be supported by 
records containing otoscopic description and tym-
panometric findings.
The exclusion criteria were: concomitant sys-
temic diseases; craniofacial, neuromuscular, 
immunological, syndromic or defined genetic 
abnormalities; chronic eardrum perforation; previ-
ous ear surgery or adenoidectomy; neurosensory 
hearing loss; immunomodulatory treatment; vita-
min D supplementation or complementary and 
alternative medicines assumption; acute febrile ill-
ness; and upper respiratory tract infection or antibi-
otic therapy in the previous 14 days.
Interventions
Upon enrolment, a complete clinical history was 
taken, and the child’s gender, age and allergies 
(documented by a positive skin prick test or radio-
allergosorbent tests and serum IgE levels within 
the previous 12 months) were recorded.
Upon enrolment and 3 months later, all of the 
children underwent a detailed otolaryngological 
clinical examination including:
•• Pneumatic otoscopy and otomicroscopy 
aimed at evaluating the integrity, colour, 
mobility, position, lightening and translu-
cency of the tympanic membrane, and detect-
ing any signs of middle ear inflammation. 
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Impaired otoscopy was defined as the pres-
ence of changes in the tympanic membrane, 
such as fibrotic scars, tympanosclerosis, var-
iable opacity, abnormal air-fluid levels and 
retraction pockets.
•• Tympanometry, which was used to assess the 
presence of impaired tympanic membrane 
mobility (on the basis of the presence of a 
type B or C tympanogram).
•• Hearing tests (i.e. conditioned play audiom-
etry in children aged <5 years or supralimi-
nar pure-tone audiometry in children aged 
⩾6 years) with an auditory threshold assess-
ment (expressed in decibels, dBs) conducted 
by an experienced audiologist.
Upon enrolment, the patients were randomised 1:1 
via a random number generator to:
•• the control group, which received the admin-
istration of normal 0.9% sodium chloride 
saline solution (3 mL per nostril) by means 
of a micronised nasal douche that nebulises 
particles with a median aerodynamic diame-
ter of >10 micron (Rhinowash, Air Liquide 
Medical Systems Italy S.p.A., Brescia, Italy) 
once a day (in the evening) for 15 days a 
month for 3 consecutive months;
•• the study group, which received the adminis-
tration of 9 mg of sodium hyaluronate (Yabro, 
IBSA Farmaceutici Italia S.r.l., Lodi, Italy) 
in 3 mL of a 0.9% sodium saline solution (3 
mL of this solution per nostril) by means of 
the same type of a micronised nasal douche 
once a day (in the evening) for the same 
period of treatment.
The compliance to the assigned treatment was 
evaluated by counting the number of dispensed and 
returned phials.
Statistical analysis
The sample size was determined on the basis of the 
primary endpoint, which was to evaluate the impact 
of the topical administration of an HA-based solu-
tion on the otoscopic and tympanometric signs of 
middle ear effusion, and was computed using pub-
lished data regarding the efficacy of tube insertion 
in reducing the prevalence of middle ear effusion 
in children with chronic OME.11 Assuming a 
standard deviation of 0.20, it was calculated that 58 
participants in each group would lead to a beta 
error margin of 0.20, with an alpha value of 0.05 
and a power of 80%.
The results are given as absolute numbers and 
percentages, or as arithmetical mean values ± stand-
ard deviation. The dichotomous outcomes were 
analysed using contingency table analysis and con-
tinuous variables using non-parametric tests.
A P value of <0.05 was considered statistically 
significant, and the data were analysed using 
STATA 10.0 software (StataCorp, College Station, 
TX, USA).
Results
Eight of the 130 enrolled children were excluded 
because they refused to attend the follow-up visit 
and six because of adenoidectomy performed at 
other hospitals during the follow-up. The final 
analysis was therefore based on the findings relat-
ing to 116 children (57 boys, 49.1%; mean age, 
62.9 ± 17.9 months): 58 in the control group (28 
boys, 48.3%; mean age, 63.7 ± 2.6 months) and 58 
in the study group (29 boys, 50.0%; mean age, 62.1 
± 2.2 months). The two groups were comparable in 
terms of their baseline demographic and clinical 
characteristics. Impaired otoscopy was detected in 
92 of the 116 patients (79.3%), conductive hearing 
loss (CHL) in 101 patients (87.1%) and impaired 
tympanometry in 102 patients (87.9%). All of these 
patients successfully completed the treatment pro-
tocol as no phials were returned at the follow-up 
visit and no untoward effects were reported in 
either group.
At the time of the follow-up visit, the prevalence 
of patients with impaired otoscopy was signifi-
cantly lower in the study group (36/58, 62.1% ver-
sus 47/58, 81.0%; P value = 0.024) compared to 
baseline but the difference was not significant in 
the control group (40/58, 68.9% versus 45/58, 
77.6%); there was also a statistically significant 
reduction in the prevalence of patients with 
impaired otoscopy in the study group when the left 
(P value = 0.020) and right ear (P value = 0.049) 
were separately analysed, but not in the control 
group (Table 1).
In comparison with baseline, the prevalence of 
patients with impaired tympanometry at the end of 
the follow-up period was significantly lower in the 
study group (42/58, 72.4% versus 51/58, 87.9%; P 
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value = 0.047) but not in the control group (48/58, 
82.7% versus 51/58, 87.9%); and this was con-
firmed by the separate assessments of the left (P 
values = 0.046 versus n.s., respectively, for the 
study and the control group) and right ears (P val-
ues = 0.036 versus n.s., respectively, for the study 
and the control group) (Table 1).
The reduction in the prevalence of patients with 
CHL (38/58, 65.5% versus 51/58, 87.9%; P value 
= 0.008) and those with moderate CHL (3/58, 5.2% 
versus 11/58, 19.0%; P value = 0.048) was again 
significant in the study group, but not in the control 
group. The mean auditory threshold had also sig-
nificantly improved by the end of treatment in the 
study group (28.6 ± 1.5 dB versus 33.3 ±1.6 dB; P 
value = 0.004) but not in the control group. 
However, there was no statistically significant 
reduction in the prevalence of patients with pan-
tonal CHL in either group (Table 2).
Discussion
After 3 months of intermittent HA-based treat-
ment, there was a statistically significant improve-
ment in almost all of the clinical and audiological 
outcomes of the children in the study group. HA 
was more effective than normal saline solution in 
improving the otoscopic, tympanometric and audi-
ometric parameters, and the children receiving HA 
experienced a significant improvement in the mean 
auditory threshold, whereas there was no signifi-
cant difference in the control group. Finally, by the 
end of the follow-up period, only the study group 
showed a significant reduction in the prevalence of 
children with CHL and those with moderate CHL, 
although there was no significant difference in the 
prevalence of patients with pantonal CHL in either.
One randomised and controlled pilot study of 
75 children with recurrent upper airway tract 
infections has found that nasal washes with 
sodium hyaluronate is superior to saline treatment 
in improving ciliar motility, cytological, micro-
biological and clinical outcomes,8 but the effect 
of topical treatment with HA in children with 
recurrent or chronic middle ear inflammation has 
not been previously investigated. It can be specu-
lated that the positive effect of HA on our patients 
was attributable to its homeostatic properties12 
and its anti-adhesive and anti-biofilm activity 
against the bacteria responsible for upper respira-
tory tract infection.5 It has been shown that HA 
plays a role in regulating vasomotor tone and 
Table 1. Prevalence of impaired otoscopy and impaired tympanometry (type B or type C tympanograms) in the control and study 
groups.
Patients, n (%) Left ear, n (%) Right ear, n (%)
Otoscopy Group Control Study Control Study Control Study
 Pre 45 (77.6) 47 (81.0) 37 (63.3) 43 (74.1) 40 (69.0) 41 (70.7)
 Post 40 (68.9) 36 (62.1) 36 (62.1) 31 (53.4) 33 (56.9) 31 (53.4)
 P value n.s. 0.024 n.s. 0.020 n.s. 0.049
Tympanometry Group Control Study Control Study Control Study
 Pre 51 (87.9) 51 (87.9) 45 (77.6) 46 (79.3) 46 (79.3) 51 (87.9)
 Post 48 (82.7) 42 (72.4) 42 (72.4) 37 (63.3) 38 (65.5) 42 (72.4)
 P value n.s. 0.047 n.s. 0.046 n.s. 0.036
n.s., non-significant.
Table 2. Prevalence of conductive hearing loss in the control and study groups.
Group Patients with HL,  
n (%)
Mean threshold* ± sd 
(dB)
Patients with moderate† HL, 
n (%)
Patients with pantonal HL, 
n (%)
Control Study Control Study Control Study Control Study
Pre 50 (86.2) 51 (87.9) 32.8 ± 1.4 33.3 ±1.6 12 (20.7) 11 (19.0) 47 (81.0) 43 (74.1)
Post 43 (74.1) 38 (65.5) 33.1 ± 1.4 28.6 ± 1.5  4 (6.9)  3 (5.2) 43 (74.1) 49 (84.5)
P value n.s. 0.008 n.s. 0.004 n.s. 0.048 n.s. n.s.
*The mean threshold of both ears at air conduction thresholds of 500, 1000, 2000 and 4000 Hz.
†A mean threshold in both ears of 40–60 dB at air conduction thresholds of 500, 1000, 2000 and 4000 Hz.
HL, hearing loss; n.s., non-significant.
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mucous gland secretion, modulating inflamma-
tory airway processes12 and improving mucocili-
ary clearance of the upper respiratory tract.6,8 
Further studies would be welcome to assess the 
possible effect of HA on ciliar motility in children 
with recurrent or chronic middle ear disease.
In conclusion, our findings confirm the safety of 
intermittent treatment with a topical nasal sodium 
hyaluronate solution and are the first to document 
its beneficial effect on clinical and audiological 
outcomes in children with OME and/or a history of 
RAOM associated with chronic adenoiditis. This 
suggests that the treatment protocol can be pro-
posed as a first-line treatment in children with 
recurrent or chronic middle ear inflammation 
before considering surgery.
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